快而精医药获机构评级更新，股价表现相对稳健

Core Viewpoint - Multiple Wall Street institutions have updated their ratings and target prices for QGEN.N, reflecting a positive outlook on the company's performance and growth potential [1][2] Group 1: Ratings and Target Prices - Morgan Stanley maintains a "Buy" rating with a target price of $60 [1] - Citigroup holds a "Hold" rating, raising its target price from $52.86 to $55 [1] - Barclays maintains a "Buy" rating, increasing its target price from $55 to $58 [1] - Baird downgraded its rating to "Hold," but raised its target price from $48.42 to $53 [1] Group 2: Financial Performance Expectations - The forecast for Q1 2026 includes revenue of approximately $504 million, representing a year-over-year growth of 7.57% [1] - Expected net profit for the same period is around $114 million, showing a year-over-year increase of 3.07% [1] - The company's financial performance is a key factor influencing stock price movements [1] Group 3: Stock Performance - Over the recent week (February 6 to February 12, 2026), QGEN.N's stock price fluctuated between $50.53 and $51.71, with a volatility of 2.32% and a trading volume of approximately $361 million [1] - As of February 12, the stock closed at $51.13, with a slight increase of 0.14%, while the Nasdaq index fell by 1.55% and the life sciences sector declined by 2.59%, indicating relative stability in the company's performance [1] Group 4: Recent Events - On February 6, 2026, several institutions updated their ratings, with target prices moving to a range of $53 to $60, reflecting market divergence and focus on growth [2] - The company's fiscal year 2025 report indicated a revenue increase of 5.65% and a net profit surge of 408.28%, although there have been no significant company announcements recently [2]